VANCOUVER, British Columbia, March 6, 2013 /PRNewswire/ -- Abattis Bioceuticals Corp. (the "Company" or "Abattis") (OTC PINK: ATTBF) (CNSX: FLU), announces it has signed a letter of intent with Crudessence Kombucha Inc. ("RISE") to acquire the worldwide exclusive license "the License" to produce, distribute, market and sell a Kombucha tea infused or blended with additional nutraceutical and bioceutical formulas developed and owned by Abattis and its subsidiaries. Under the Terms of the Agreement will acquire "the License" in exchange for 500,000 shares of Abattis at a deemed price of CAD $0.20 and a running technology royalty fee to "RISE".
Rise Kombucha is a highly successful brand sold across Canada, the purpose of the LOI is to enable Abattis to initially bring a new brand of Cannabidiol CBD infused probiotic functional beverages to the markets starting in Washington and Colorado, the brand will be launched as "Cannabucha Sun Rise™" this product will be the first of its kind with infused Cannabidiol "CBD" with the probiotic effects to create one of the best possible health drinks in the world. Kombucha is a microbial culture of various bacteria and yeast species. Fermentation of the culture in naturally sweetened tea produces numerous organic acids such as ascetic acid, gluconic acid, malic acid, amino acids and enzymes, and polyphenols (e.g. catechins) that improve overall health.
Mr. Mike Withrow , Chief Executive Officer on behalf of the Company, stated, "We are very excited to enter into the emerging US CBD infused product markets, leading with a Kombucha beverage which is fast growing in popularity. Kombucha is a perfect delivery beverage for CBD's because it is a functional probiotic drink that strengthens the immune system, balances intestinal flora, stimulates digestion, combats stress, and incr
|SOURCE Abattis Bioceuticals Corp.|
Copyright©2012 PR Newswire.
All rights reserved